A Convergence of Chemistry And Biology To Create Better Medicine
Ambrx®, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties. We call this process Protein Medicinal Chemistry™.
Protein Medicinal Chemistry™ can optimize any protein or antibody to create potentially best-in-class therapeutics such as long-acting proteins, bi-specifics and antibody drug conjugates. The Ambrx advantage allows us to safely and effectively target cytotoxic agents or recruit effector function to tumor cells (oncology) or modulate biological pathways implicated in disease areas such as autoimmune, metabolic and cardiovascular.
At Ambrx, we are dedicated to assembling and developing an exceptional team and a novel technology to create the next generation of protein-based medicines.
Board of Directors
John D. Diekman, Ph.D. | Chairman of the Board
John D. Diekman, Ph.D. has served as Chairman of our board of directors since August 2003. Dr. Diekman is a founder and Managing Partner of 5AM Ventures, where he has served since 2002. Dr. Diekman has also been a Director of Aravis Ventures, an international early-stage life science fund, since 2001. Prior to founding 5AM Ventures, from 1997 to 2002, Dr. Diekman founded and served as Managing Director of Bay City Capital, a life sciences investment firm. From 1995 to 2002, Dr. Diekman served as Chairman of Affymetrix, Inc., for which he also served as Chief Executive Officer from 1995 to 1997. Dr. Diekman currently also serves on the board of directors of each of Cellular Research, Inc., Calibrium Biotech, Igenica, Inc., PhaseRx Pharmaceuticals, Inc. and Wildcat Discovery Technologies, Inc. He previously served on the board of directors of each of Aravis Ventures, Affymetrix, Inc., BioOne Capital Pte Ltd., Envoy Therapeutics, Inc., InGenuity Systems, Inc. and Kalypsys, Inc. He is a Trustee of Princeton University, a former Director of The California Institute of Technology, and a former Chairman of the Board of The Scripps Research Institute. Dr. Diekman holds an A.B. in Organic Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University.
Eric H. Bjerkholt
Eric H. Bjerkholt has been a member of our board of directors since May 2014. Mr. Bjerkholt has served as the Executive Vice President, Corporate Development and Finance and Chief Financial Officer of Sunesis Pharmaceuticals, Inc., or Sunesis, a public biopharmaceutical company, since January 2012. Mr. Bjerkholt has served as Senior Vice President and Chief Financial Officer of Sunesis since January 2004, and served as Senior Vice President, Corporate Development and Finance and Chief Financial Officer of Sunesis from February 2007 through January 2012. From January 2002 to January 2004, Mr. Bjerkholt served as Senior Vice President and Chief Financial Officer at IntraBiotics Pharmaceuticals, Inc., a pharmaceutical company focused on the development of antibacterial and antifungal drugs for the treatment of serious infectious diseases. Earlier, he was a co-founder of LifeSpring Nutrition, Inc., a privately held nutraceutical company, and from May 1999 to March 2002 served at various times as its Chief Executive Officer, President and Chief Financial Officer. Mr. Bjerkholt serves as a member of the board of directors of StemCells, Inc., a biotechnology company. Mr. Bjerkholt was an investment banker at J.P. Morgan & Co. from 1990 to 1997 and holds a Cand. Oecon degree in Economics from the University of Oslo and an M.B.A. from Harvard Business School.
Christopher Fuglesang, Ph.D., J.D.
Christopher Fuglesang, Ph.D., J.D. has served as a member of our board of directors since March 2012. Dr. Fuglesang has worked at Tavistock Life Sciences since 2005, where he co-manages venture capital and private equity investments in life sciences companies. Dr. Fuglesang is also the co-founder of Boxer Capital LLC, the primary vehicle in which Tavistock Group invests in public healthcare companies. Earlier in his career with Tavistock Life Sciences, Dr. Fuglesang handled and supervised a variety of transactions, including mergers and acquisitions, joint ventures and other strategic collaborations in the healthcare space. He also has experience in intellectual property management, licensing and corporate development. Dr. Fuglesang is currently also a member of the board of directors of Eidogen-Sertany. Dr. Fuglesang holds a Ph.D. in chemical physics from the University of California, Los Angeles, a J.D. from the Boston University School of Law and a B.S. in each of chemistry and physics from the University of California, Los Angeles.
Barry Greene has served as a member of our board of directors since January 2014. Mr. Greene has served as the President and Chief Operating Officer of Alnylam Pharmaceuticals, Inc., or Alnylam, a public biopharmaceutical company, since December 2007. Mr. Greene has served as Chief Operating Officer of Alnylam since October 2003, and served as Treasurer from February 2004 through December 2005. From February 2001 to September 2003, Mr. Greene served as General Manager of Oncology at Millennium Pharmaceuticals, Inc., or Millennium, a biopharmaceutical company. He focused on global strategy and execution for Millennium’s oncology business to guide near- and long-term research, development and commercialization and was involved in the successful approval and launch of VELCADE (bortezomib). Earlier, he was Vice President of Strategic Integration with responsibility for the AstraZeneca North America post-merger integration and Vice President of Marketing and Customer Services for AstraZeneca. Prior to his work with AstraZeneca, he was a partner with Andersen Consulting, where he was responsible for the pharmaceutical and biotechnology marketing and sales practice. Mr. Greene serves as a member of the board of directors of each of Acorda Therapeutics, Inc., a public biotechnology company, and Karyopharm Therapeutics, Inc., a private pharmaceutical company. He previously served on the board of directors of each of Regulus Therapeutics, Inc. and Intercept Pharmaceuticals, Inc. Mr. Greene holds a B.S. in Industrial Engineering from the University of Pittsburgh.
SHEILA GUJRATHI, M.D.
Sheila Gujrathi, M.D. has been a member of our board of directors since February 2014. She is currently the Chief Medical Officer of Receptos, Inc., a position she has held since June 2011. She joined Receptos from Bristol-Myers Squibb, where she was Vice President of the Global Clinical Research Group in Immunology from 2008 to 2011. Prior to joining Bristol-Myers Squibb, Dr. Gujrathi worked at Genentech, where she held roles of increasing responsibility in the Immunology, Tissue Growth and Repair clinical development group from 2002 to 2008. From 1999 to 2002, Dr. Gujrathi was a management consultant at McKinsey & Company in the healthcare practice, where she provided strategic advice on a variety of projects in the healthcare and pharmaceutical industry. Dr. Gujrathi received her B.S. with highest distinction in Biomedical Engineering and M.D. from Northwestern University in their accelerated honors program in Medical Education. She completed her internal medicine internship and residency at Brigham and Women’s Hospital, Harvard Medical School and is board certified in internal medicine. She received additional training at the University of California, San Francisco and Stanford University in their Allergy and Immunology Fellowship Program.
Lawson Macartney, Ph.D., B.V.M.S.
Lawson Macartney, Ph.D., B.V.M.S. has served as our President and Chief Executive Officer and as a member of our board of directors since February 2013. Prior to joining us, Dr. Macartney served at Shire AG, a specialty biopharmaceutical company, as Senior Vice President of the Emerging Business Unit from 2011 to 2013, where he was responsible for discovery initiatives through Phase 3 development of Shire’s Specialty Pharmaceutical portfolio. Prior to joining Shire AG, he served at GlaxoSmithKline, or GSK, a pharmaceutical company, from 1999 to 2011, serving as Senior Vice President of Global Product Strategy and Project/Portfolio Management from 2007 to 2011, as Senior Vice President, Cardiovascular and Metabolic Medicine Development Center from 2004 to 2007, and as Vice President, Global Head of Cardiovascular, Metabolic and Urology Therapeutic Areas from 1999 to 2004. Prior to joining GSK, Dr. Macartney was employed at Astra Pharmaceuticals from 1998 to 1999 in leadership roles in operations, marketing and sales, and served as Executive Director, Commercial Operations at AstraMerck, Inc., a pharmaceutical company, from 1996 to 1998. Dr. Macartney also currently serves as a member of the board of directors of Viking Therapeutics, Inc. Dr. Macartney received his Ph.D. from Glasgow University in Scotland in 1982, where he was a Royal Society Research Fellow, and his B.V.M.S. (equivalent to a D.V.M.) in 1979 from Glasgow University Veterinary School. He is also trained in diagnostic pathology and is a Fellow of the Royal College of Pathologists.
Allan Marchington, Ph.D.
Allan Marchington, Ph.D. has served as a member of our board of directors since June 2006. Dr. Marchington has served as a Partner of Apposite Capital LLP since 2006. He also currently sits on the board of directors of each of Ambit Biosciences Corp., RuiYi Inc., Convergence Pharmaceutical Holdings Ltd., Calchan Holdings Ltd., The BioIndustry Association, Apposite CP1 LP and Central Garage (1958) Ltd.. He previously served on the board of directors of each of Millennium Pharmaceuticals (Europe) Ltd., Cambridge Combinatorial Ltd., Cambridge Discovery Chemistry Ltd. and Oxford Molecular PLC. From 2000 to 2003, Dr. Marchington served as Senior Vice President, Productivity of Millennium Pharmaceuticals, where he was responsible for Millennium’s European activities and a majority of the company’s technology investments. From 1997 to 2000, Dr. Marchington served as the founder and Chief Executive Officer of Cambridge Discovery Chemistry. From 1990 to 1996, Dr. Marchington was a medicinal chemist at Pfizer Central Research in Sandwich, UK. Dr. Marchington holds a Ph.D. in Organic Synthetic Chemistry and B.Sc. in Chemistry from the University of Liverpool.
David B. Singer
David B. Singer has served as a member of our board of directors since March 2005. Since 2004, Mr. Singer has been an employee or Limited Partner at Maverick Capital, Ltd., a private investment firm, or an affiliate thereof. Mr. Singer is responsible for the firm’s private investments globally. Previously, Mr. Singer served as the founding President and Chief Executive Officer of three healthcare companies. He served on the board of directors of each of Pacific Biosciences of California, Inc. from December 2006 to May 2013, Affymetrix, Inc. from 1993 to 2008, Corcept Therapeutics Inc. from 1998 to 2008 and Oscient Pharmaceuticals Corporation from 2004 to 2006. Mr. Singer has also served as the Senior Financial Officer of two publicly traded companies. Mr. Singer received an M.B.A. from Stanford University and a B.A. in History from Yale University.
Ambrx and Zhejiang Hisun Pharmaceutical to Collaborate on the Development and Commercialization of Bispecifics for Cancer
SAN DIEGO and TAIZHOU CITY, China, April 29, 2014 – Ambrx Inc. and Zhejiang Hisun Pharmaceutical Company Ltd. (SSE Code:...
SAN DIEGO, Feb. 24, 2014 -- Ambrx Inc. today announced that Sheila Gujrathi, M.D., has joined its board of directors....
SAN DIEGO, Feb. 5, 2014 -- Ambrx Inc. today announced the appointment of Barry Greene to its board of directors....